Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the research and development of T cell-based CAR T cell therapies ( Chimeric Antigen Receptor) for the treatment of cancer, today announced its decision to voluntarily suspend the Phase 1b study CYAD-101-002 (KEYNOTE-B79) (NCT04991948).
The CYAD-101-002 study is part of a collaboration with MSD, a trade name of Merck & Co., Kenilworth, NJ, USA, through one of its subsidiaries. The clinical trial evaluates the Company’s investigational therapy, CYAD-101, which are allogeneic NKG2D CAR T cells expressing the TCR Inhibitory Molecule (TIM), administered simultaneously with FOLFOX chemotherapy, and followed by anti-PD1 therapy of MSD, KEYTRUDA® (pembrolizumab), in Patients with Refractory Metastatic Colorectal Cancer.